Neuland Laboratories (524558) Q2 24/25 earnings summary

Executive summary

• Q2 FY25 total income was INR 315.2 crores, down from INR 422.8 crores in Q2 FY24, reflecting the lumpy and volatile nature of the business, especially in the CDMO and specialty GDS segments.

• Q2FY25 results were below recent quarters but aligned with earlier guidance, reflecting the business's inherent volatility; management remains focused on long-term growth through customer acquisition, capability expansion, and process optimization.

• Unaudited financial results for the quarter and half year ended September 30, 2024, were approved by the Board on November 6, 2024.

• Management expects FY25 to be flat compared to FY24, with growth momentum anticipated to return in FY26, supported by new facility completion and a strong order pipeline.

• The company continues to focus on productivity, cost optimization, and long-term sustainability, with investments in facility upgrades and capacity expansion.

Financial highlights

• Q2 FY25 EBITDA was INR 65.7 crores (20.8% margin), down from Q2 FY24 due to lower contribution.

• Gross margin for Q2 FY25 was 56.3%, compared to 59.8% in Q2 FY24.

• Profit after tax for Q2 FY25 was INR 32 crores, down from INR 89.1 crores in Q2 FY24; EPS for the quarter was INR 24.9.

• H1 FY25 revenues were INR 759.6 crores, a 3.3% decline year-over-year; H1 EBITDA was INR 194.3 crores, down from INR 239.6 crores in H1 FY24.

• Free cash flow generated in H1 FY25 was INR 45.8 crores.

Outlook and guidance

• FY25 is expected to be flat versus FY24, a revision from earlier moderate growth expectations, due to execution delays and customer-driven project shifts.

• High growth is anticipated from FY26 onward, driven by new facility ramp-up and commercial launches in the CMS segment.

• Management remains cautiously optimistic, citing a strong order pipeline and favorable medium- to long-term industry environment.